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A heteroplasmic point mutation (transition A to G at position. 3243 in the mitochondriai tRNA LeU(uuR) gene is indicative for myo-encephalopathy 
with lactic acidosis and stroke-like episodes (MELAS). Decreased respiratory chain complex activities measured in different tissues from four 
patients with MELAS syndrome do not correlate with the proportion of mutated mitochondrial genome. 
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1. INTRODUCTION 
Myo-encephalopathy with lactic acidosis and stroke- 
like episodes (MELAS) is a rare mitochondrial (mt) 
disorder. Three independent groups [l-3] reported that 
in Japanese patients the disease is accompanied by a 
point mutation (transition A to G) of the mitochondrial 
genome within the tRNALeU~““” at the Cambridge 
nucleotide number 3243. Recently we have confirmed 
these results in four Caucasian cases with MELAS [4]. 
It was speculated that this mutation might be the main 
cause of the disease. As respiratory chain enzymes are 
partially coded by the mt genome we asked the question 
of how activities of these enzymes are altered by the 
MELAS mutation. Here we describe the respiratory 
chain activities in muscle samples of four MELAS pa- 
tients and in five different tissues from one particular 
MELAS case and compare the results with the propor- 
tions of wild-type mtDNA still present in these tissues. 
hemianopsia, hemiparesis, ataxia, frontal headache and generalized 
tonocionic seizures. High blood lactate levels together with ‘ragged 
red fibers’ in skeletal muscle histology confirmed the diagnosis of 
MELAS. His mother and two brothers have sensoneurai deafness and 
diabetes meltitus. 
Cuse 2 is the cider brother of case 4. At the age of 14 years he 
presented with muscle weakness and a muscle biopsy was taken. 
Histologically ‘ragged red fibers’ and lipid accumulations were 
found. During the passed three years he had several stroke-like 
episodes and developed cortical blindness, hemiparesis, hearing loss, 
somnolence as welt as intellectual retardation. 
Case 3 is a 19-year-old girt with mental retardation and short 
stature. At the age of 16 she had a first attack of headache with 
vomiting. High blood lactate levels and histologically finding of 
‘ragged red fibers’ with lipid accumulation in skeletal muscle canfirm- 
ed the MELAS syndrome. 
Case 4 was the eider sister of case 2. She showed retarded deveiop- 
menl and presented with muscle weakness at the age of 7 years. At 
that time a muscle biopsy was taken and histologically lipid accumuia- 
tion and an increased number of mitochondria wcrc found. During 
the last two years of her life she became more and more dement, had 
scvcrai stroke-like episodes and developed facial patsy, convulsions, 
hemiparesis, cortical blindness, sensoneurai hearing toss. She died at 
the age of 12 years. 
2. PATIENTS AND METHODS 
2. I. Patients 
Case / is a 38-year-old man, who had Ihc first symptoms of the 
discasc ;II Itie nyc al’ IO. AI the age of 30 hc had scvcrui cpisodcs of 
Alrbrevirrrionr: hi>. lxw lXlir&i CtJEO, chronic pragrcsslvc cxtertlal 
ui~htllaln~~plcgitl; MELAS, mitachendriol lllyopa~lly, 
e~wq~lxalopa~l~p. lactic acidosis end strokc.likc ~pisoclcs; MEKRF, 
myaclenic epilepsy with ragpcd red fibers; 1111, mitarhetrdrial 
Carrespondence udtlrrw li.-0. Cicrbilr, Instirut IIir Kliniechr 
Chcmic, %&it. Krankrllhaus MOn~hctr.S~h\v~bill~, Ktitnrr I%w I, 
8000 M(lii&en JO, Germany 
2.2. Mctttocls 
DNA cxtraclion and aclivhy measuremcms of the respiratory chain 
COIII~~CXCS were performed in muscie biopsy samples (casts I, 2 illId 
3) or in post-mortem autopsy tissues (case 4). Ail biopsies were taken 
for diagnostic reasons in vivo after obtaining informed consem of the 
patients. 
Extrac/ion and tabrtting af DIVA. Total DNA preparation was per- 
formed hy standard protcinasc K proccdurcas dcscribcd [S]. MtDNA 
as probe for hybridization NTIS purified from human pinrenia arcar- 
ding to Drouin (61 and iabcicd with the ECL (enhanced 
~hc~niiulnincscetl~c) gcnc dc~cctinn system as reeomnrcndcd by the 
supplier (Anicrxham, Germany). 
Amtyrts qf nr/DNA. Total prticnt DNA (2-3 1’~) was digested 
avcrnigtrl whh IO U rcotrictian cndonu&tse &WI (13ochringcr 
Maiitihcim, Grrntany) according to the inunufa~~urcrs iiir~rucfions, 
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subjected to electrophoresis on 1.0% agarose gels, transferred to 
nylon membranes (Hybond-N, Amersham, Germany) and further 
processed as recommended by the manufacturer for the ECL system. 
MtDNA/I-kb ladder (BRL. Germany) was used as marker DNA. Ex- 
posure times between 10 s and 10 min were sufficient to get scannable 
signals (X-Omat RF, Kodak, Germany). Densitometry was per- 
formed using the Elscript 400 UVR Scanner (Hirschmann, Munich). 
Measurements of the respiratory chain complexes (complex I: 
NADH-ubiquinone oxidoreductase; complex II + III: succinate- 
cytochrome c oxidoreductase; complex IV: cytochrome c oxidoreduc- 
tase; complex I-IV: NADW-02 oxidoreductase) were performed as 
described elsewhere [5,7]. 
3. RESULTS 
Fig. I. Southern blot after digestion by Apol of mtDNA from cardiac 
muscle (CM4) and liver (L4) of case 4, and from skeletal muscle (SM3) 
of case 3 and a healthy control (C). The wild-type pattern is shown in 
lane C, where 5 different bands can be seen (M,: 7190 bp, 3822 bp, 
2965 bp, 1596 bp, and 1016 bp). Mutated MELAS mtDNA always 
shows two additional bands of approximately 1.8 kb and 1.2 kb, 
which result from a fifth recognition site in the 2965 bp fragment. As 
a result of heteroplasmy. this latter fragment is still present in the 
MELAS tissues. 
Digestion with the endonuclease ApaI usually cuts 
the mtDNA at positions 16459, 9269, 8253, 4431 and 
1466 and produces five fragments of 7190 bp, 3822 bp, 
2965 bp, 1576 bp and 1016 bp in length (Fig. 1, lane 
C). The transition A to G at position 3243 creates a new 
restriction site for the enzyme leading to a cleavage of 
the 2965 bp fragment into two smaller fragments with 
molecular weights of 1780 bp and 1185 bp. The 
resulting seven band pattern was found in skeletal 
muscle samples from all of our four MELAS patients as 
we11 as in five different tissues from case 4 [4]. As in all 
MELAS tissues, wild-type and mutated mtDNA coex- 
isted together and the genomes were heteroplasmic. 
&a1 digestion of mtDNA from skeletal muscle of five 
controls yielded the expected normal five band pattern. 
Fig. I shows the results for cardiac muscle (CM4) and 
liver (L4) of case 4, for skeletal muscle of case 3 @MS), 
and for skeletal muscle of one representative control 
(C). 
Using densitometric scanning we found that the pro- 
portion of preserved wild-type mtDNA in skeletal 
muscle ranged from 7% in case 1 to 68% in case 4 
(Fig. 2A). A similar range of variation was seen in the 
five different tissues from case 4, where the wild-type 
mtDNA varied from 19% in brain up to 68010 inskeletal 
muscle (Fig. 3A). 
Fig. 2 compares the proportion of non-mutated 
mtDNA with activity values of the respiratory chain 
complexes I, II -t III and IV in skeletal muscle from the 
four MELAS patients. Complex I deficiency and to a 
lesser extent also decreased complex IV activity was 
found in patients 1 and 4, while in all cases no reduced 
complex II + III activities were found. Cases 1-3 show- 
ed a very low proportion of normal mtDNA between 
7% and 16% while in case 4 we found 68%, There was 
no clear-cut correlation between the proportion of the 
mutated mtDNA and reduced enzyme activities. In par- 
ticular cases 2 and 3 had nearly the same high amount 
of mutated mtDNA in muscle. In contrast o cast 2 who 
had a severe complex 1 defect, case 3 had biochemically 
normal values. Comparison of the DNA data with the 
biochemical activity values measured in five different 
tissues from case 4 yielded similar results (Fig. 3). 
Although the proportion of mutated mtDNA wat lower 
CM4 L4 SM3 6 
in skeletal muscle than in diaphragm, liver and heart all 
respiratory chain activities were measured within the 
reference ranges in these three latter tissues. This was 
not the case in skeletal muscle. In brain a complex I 
deficiency was detectable. 
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Fig. 2. (A) Proportion of wild-type mlDNA from skclctaf muscle 
(SMI) of four palientr with MELAS as percent of total mtDNA; index 
i deaotes the case number, Depicted values arc means of l-3 
dcnsitomctric scannings. (0) Ulochemical measurements hi muscle 
homogenutcs of complex I (NADH-ubiquinone oxidoreductase), 
complex II + III (succinntr-Cyt c oxidoreduetnse) and somplcx IV 
(cylochroaie c oxidaxe), complex I-IV (NADW03 oxidorcductnse). 
Activity is cxprrxsed uxenrol/~ni~~ and gram of noe~colla#cn prorcin. 
Meusurcmcnls were done at least in triplicalcn; avereyc valucn arc 
given. 
68 
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Fig. 3. (A) Proportion of wild-type mtDNA extracted from skeletal 
muscle (SM& cardiac muscle (CM& brain (B4), liver (I-4) and 
diaphragm (Da) of case 4: index denotes the case number. Depicted 
values are means of l-3 densitometric scannings. (B) Biochemical 
measurements of respiratory chain complex activities in the different 
tissues. Activity is expressed as described in Fig. 2. Measurements 
were done at least in triplicates per tissue, average values are given. 
Control ranges are given in parentheses. 
4. DISCUSSION 
13 polypeptides (subunits of the respiratory chain 
complexes), 2 ribosomal RNAs and 22 tRNAs are en- 
coded by the mitochondrial genome. Among the 
h&erogenous group of mitochondrial encephalomyo- 
pathies deletions of the mtDNA were found in patients 
with chronic progressive external ophthalmoplegia 
(CPEO) and Kearns-Sayre syndrome [5,8- 131, while 
defined point mutations were observed in patients with 
Leber’s opticus neuropathy 1141 and in patients with 
myoclonus epilepsy with ragged red fibers (MERRF) 
[15,16]. Sequencing of the mtDNA from patients with 
MELAS yielded a transition A to G at position 3243 of 
the mt genome within the tRNAL’“(“UR) gene. This 
mutation was reported in 36141 Japanese patients with 
MELAS by three independent groups [l-33, but was 
not found in 83 controls and in 5 cases with MERRF 
[ 11. One patient with CPEO, who exhibited no larger 
mtDNA deletion, also had the mutation at position 
3243 [ 11 a We could confirm these results in four Cauca- 
sian patients with MELAS [43. Thus the fact that the A 
to G transition within the tRNALeU seems to be specific, 
but not exclusive is not restricted to one ethnic group. 
The adcnine at position 3243 within the DHU loop of 
the mitochondrial tRNALcu(““K) is functionally con- 
served during evolution [ 1,3]. A second function of the 
gene which encodes for the tRNAt,c”(UUK) is to play a 
role in the partial termination of the heavy strand 
transcription causing a more frequent ribosomal RNA 
synthesis [17). The high proportion of mutated mtDNA 
found in some of our patients (>90%) indicates that 
most of the cells should be affected. Assuming a direct 
sorrelation between the molecular and biochemical 
level this should be reflected by lowered or missing ac- 
tivities of the respiratory chain complexes, which are 
partially encoded by the mtDNA. As we show here, this 
is not the case. There is no clear-cut correlation between 
the proportion of mutated mtDNA and reduced com- 
plex I and/or IV activities in skeletal muscle or other 
tissues. Furthermore only focal complex IV deficiencies 
are usually observed histochemically in muscle samples 
from MELAS patients. Using specific antibodies in im- 
munoblot technique, Jinnai et al. [lg] demonstrated 
that beside the mitochondrially encoded subunit 2 also 
the nuclear encoded subunits 6 and 7 of complex IV 
were decreased in skeletal muscle of a MELAS patient. 
Focal complex IV defects were also obtained in skeletal 
muscle of case 3 (unpublished results) and in other 
tissues from case 4 by one of us 1191. We cannot exclude 
that the activity of mitochondrial Mg-ATPase, which 
has two mitochondrial encoded subunits, but cannot be 
measured in muscle homogenates, ismore related to the 
degree of mutated ml genome populations. Never- 
theless comparison of biochemical and molecular 
biological results for SM3 and SM4 as well as 
diaphragm, cardiac muscle and skeletal muscle in case 
4 points towards additional factors (additional muta- 
tions or nuclear influences) involved in the pathogenesis 
of this form of mitochondrial encephalomyopathies. 
Therefore the point mutation at position 3243 of the 
tRNALeUtUUR’ gene might be indicative, but is probably 
not the only cause for MELAS. A similar conclusion 
might be drawn from the fact that the clinical picture of 
this disease is dominated by cardiac and cerebral symp- 
toms although other tissues exhibit the mt mutation. 
Further studies have to be done to answer the question 
which at present unknown additional factors can ex- 
plain how genotype and phenotype are connected in this 
disease. 
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